Telix Pharmaceuticals posted an 11% increase in Q1 2026 revenue to US$230 million, reaffirmed full-year guidance, and reported progress in multiple clinical trials including its lead prostate cancer therapy TLX591-Tx.
- Q1 2026 revenue up 11% quarter-over-quarter to US$230 million
- FY 2026 revenue guidance reaffirmed at US$950–970 million
- Positive Phase 3 ProstACT trial results for prostate cancer therapy TLX591-Tx
- Regulatory submissions advanced for imaging agents TLX101-Px and TLX591-Px
- New Non-Executive Director appointment announced
Strong Revenue Growth in Q1 2026
Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) reported unaudited group revenue of US$230 million for the quarter ended March 31, 2026, representing an 11% increase compared to the previous quarter. This growth was driven primarily by the Precision Medicine segment, which recorded US$186 million in revenue, up 16% quarter-over-quarter, supported by strong sales of Illuccix® and Gozellix® imaging agents.
The company reaffirmed its full-year 2026 revenue guidance of US$950 million to US$970 million, reflecting confidence in ongoing commercial momentum and market expansion. Telix also maintained its research and development expenditure guidance of US$200 million to US$240 million, subject to achieving global commercial milestones.
Progress in Therapeutics Pipeline
Telix highlighted advances in its therapeutics pipeline, notably the ProstACT Global Phase 3 trial of TLX591-Tx, its lead prostate cancer therapy candidate. Part 1 of the trial met safety and dosimetry objectives with no new safety signals observed, and no adverse drug-drug interactions were reported when combined with standard treatments for metastatic castration-resistant prostate cancer (mCRPC), including androgen receptor pathway inhibitors and chemotherapy.
Following these results, Telix has engaged with the U.S. Food and Drug Administration (FDA) to present Part 1 data and explore eligibility for U.S. patient enrolment in Part 2 of the trial, which is already open in Australia, New Zealand, and Canada. Site activation is underway in China, Singapore, South Korea, Türkiye, the United Kingdom, and Japan, where regulatory approvals have been granted.
Additional clinical progress includes the initiation of patient recruitment for the LUTEON pivotal trial of TLX250-Tx in advanced clear cell renal cell carcinoma outside the U.S., and the enrollment of the first patient in the IPAX-BrIGHT pivotal trial of TLX101-Tx for recurrent glioblastoma, now open in multiple European countries and Australia. The SOLACE Phase 1 study of TLX090-Tx for pain management in osteoblastic bone metastases also expanded to new U.S. sites to accelerate recruitment.
Regulatory and Commercial Developments
On the regulatory front, Telix resubmitted its New Drug Application (NDA) for TLX101-Px (Pixclara®) to the FDA with additional clinical data, following prior feedback. The company also filed a Marketing Authorization Application (MAA) in Europe for Pixlumi®, aiming to broaden patient access to advanced brain imaging.
In China, the NDA for TLX591-Px (Illuccix) was accepted by the National Medical Products Administration (NMPA), marking a significant step in expanding the commercial footprint of Telix’s PSMA imaging portfolio. Illuccix is now launched in 21 countries globally, including 16 European markets, enhancing access to PSMA-PET/CT imaging and supporting future product launches.
Regarding Zircaix® (TLX250-Px), Telix has aligned with the FDA on key issues for the Biologics License Application resubmission, targeting submission in the first half of 2026.
Corporate Update
Telix announced the appointment of David Gill as a Non-Executive Director effective May 11, 2026, as part of its board renewal process. Mr Gill is expected to succeed Dr Mark Nelson as Chair in due course. The company noted Mr Gill’s extensive experience in U.S. public company governance and biopharmaceutical leadership as a valuable addition to the board.
Dr Christian Behrenbruch, Managing Director and Group CEO, commented on the quarter’s performance, highlighting the growth in U.S. dose volumes and the expanding commercial presence globally. He noted the company’s strategic focus on advancing high-value clinical programs, as evidenced by the momentum in the therapeutics pipeline during the quarter.
Bottom Line?
Telix’s Q1 results and pipeline progress reinforce its strategic focus, though regulatory and clinical milestones remain subject to typical biotech uncertainties.
Questions in the middle?
- How will the timing of FDA decisions on TLX101-Px and TLX591-Px impact Telix’s commercial rollout plans?
- What are the potential challenges in enrolling patients for the global expansion of the ProstACT Phase 3 trial?
- How might competitive developments in PSMA-targeted therapies influence Telix’s market share and pricing strategies?